SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
US Supreme Court blocks bid to overturn lower court ruling | District court found in 2023 that the generic would infringe patents owned by a Bausch subsidiary | Blockbuster drug Xifaxan is used to treat IBS with diarrhoea, and a liver-related brain disorder.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
30 April 2026 The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.
29 April 2026 The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.
28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug